Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It …
Medical - Diagnostics & Research
US, Wilmington [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 14.59 | 1.75 | 1.52 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 39.03 | 12.02 | 8.64 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.96 | 70.77 | 70.10 | |
| Cash | 21.59 | 6.56 | 5.39 | |
| Capex | -0.80 | -1.54 | -1.53 | |
| Free Cash Flow | -64.51 | 0.99 | 2.78 | |
| Revenue | -0.43 | 19.67 | 19.75 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -11.89 | 0.32 | 0.36 | |
| Operating Margin | 7.77 | 0.14 | 0.13 | |
| ROA | -63.82 | < 0.005 | 0.02 | |
| ROE | -64.44 | 0.02 | 0.05 | |
| ROIC | 1.18 | 0.02 | 0.02 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of CRL is permitted for members.
5
Growth
The "Growth Entry" for the Focus of CRL is permitted for members.
6
Leverage & Liquidity